Cancer - Many vessels, faulty gene

被引：34

作者：

Kaelin, WG ^{[1
]}

机构：

[1] Howard Hughes Med Inst, Boston, MA 02115 USA

[2] Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA

[3] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA

[4] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA

来源：

NATURE | 1999年 / 399卷 / 6733期

关键词：

D O I：

10.1038/20309

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

The von Hippel-Lindau (VHL) cancer syndrome is caused by mutations in theVHLgene, and is characterized by development of blood-vessel tumours. Production of blood vessels is normally stimulated when cells are short of oxygen. But when oxygen is plentiful, the factors that stimulate production of vessels are destroyed. It now turns out that the VHL protein is responsible for this destruction. So, when it is mutated, the result is too many vessels and tumour formation.

引用

收藏

页码：203 / 204

页数：2

相关论文

共 14 条

[1] Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal [J].

Benjamin, LE ;

Keshet, E .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (16) :8761-8766

[2] Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes [J].

Ivanov, SV ;

Kuzmin, I ;

Wei, MH ;

Pack, S ;

Geil, L ;

Johnson, BE ;

Stanbridge, EJ ;

Lerman, MI .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (21) :12596-12601

[3] The VHL tumour-suppressor gene paradigm [J].

Kaelin, WG ;

Maher, ER .

TRENDS IN GENETICS, 1998, 14 (10) :423-426

[4] Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase [J].

Kamura, T ;

Koepp, DM ;

Conrad, MN ;

Skowyra, D ;

Moreland, RJ ;

Iliopoulos, O ;

Lane, WS ;

Kaelin, WG ;

Elledge, SJ ;

Conaway, RC ;

Harper, JW ;

Conway, JW .

SCIENCE, 1999, 284 (5414) :657-661

[5] Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function [J].

Krieg, M ;

Marti, HH ;

Plate, KH .

BLOOD, 1998, 92 (09) :3388-3393

[6] Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2 [J].

Lonergan, KM ;

Iliopoulos, O ;

Ohh, M ;

Kamura, T ;

Conaway, RC ;

Conaway, JW ;

Kaelin, WG .

MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (02) :732-741

[7] The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis [J].

Maxwell, PH ;

Wiesener, MS ;

Chang, GW ;

Clifford, SC ;

Vaux, EC ;

Cockman, ME ;

Wykoff, CC ;

Pugh, CW ;

Maher, ER ;

Ratcliffe, PJ .

NATURE, 1999, 399 (6733) :271-275

[8] The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix [J].

Ohh, M ;

Yauch, RL ;

Lonergan, KM ;

Whaley, JM ;

Stemmer-Rachamimov, AO ;

Louis, DN ;

Gavin, BJ ;

Kley, N ;

Kaelin, WG ;

Iliopoulos, O .

MOLECULAR CELL, 1998, 1 (07) :959-968

[9] ROC1, a homolog of APC11, represents a family of cullin partners with an associated ubiquitin ligase activity [J].

Ohta, T ;

Michel, JJ ;

Schottelius, AJ ;

Xiong, Y .

MOLECULAR CELL, 1999, 3 (04) :535-541

[10] The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal [J].

Pause, A ;

Lee, S ;

Lonergan, KM ;

Klausner, RD .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (03) :993-998